Skip to content

Dapagliflozin in Patients with Severe Reduced Ejection Fraction Heart Failure - A Multicenter Registry Study

Dapagliflozin in Patients with Severe Reduced Ejection Fraction Heart Failure - A Multicenter Registry Study

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200055897
Enrollment
Unknown
Registered
2022-01-22
Start date
2021-04-28
Completion date
Unknown
Last updated
2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Interventions

Observation group:None

Sponsors

The First Affiliated Hospital of University of Science and Technology of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged 18 years and over; 2. Meet the diagnostic criteria for heart failure in the "Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2018" published by the Chinese Society of Cardiovascular Diseases; 3. New York cardiac function class III-IV; 4. Cardiac ultrasound examination indicating LVEF <= 40% (modified Simpson method); 5. New or no use of dapagliflozi during hospitalisation.

Exclusion criteria

Exclusion criteria: 1. Heart failure caused by restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic cardiomyopathy or uncorrected primary valvular disease; 2. eGFR 0.3 mg/dl or rise in Scr > 50% (to 1.5 times baseline) or reduced urine output (< 0.5 ml/kg/h) for more than 6 hours within 48 hours); 3. Combined diabetic ketosis or ketoacidosis; 4. Urinary tract infection or previous recurrent urinary tract infections; 5. Pregnancy or planned pregnancy during the project study period and those who refuse to use contraception or who are breastfeeding; 6. Based on the investigator judgment, the patient could not complete this study or could not comply with the requirements of this study.

Design outcomes

Primary

MeasureTime frame
NT-proBNP;

Secondary

MeasureTime frame
Echocardiographic indicators;Blood biochemical parameters;sST2;Glycosylated hemoglobin;Cardiac enzymes;Routine blood test;Urine routine;ECG;

Countries

China

Contacts

Public ContactYan Ji

The First Affiliated Hospital of University of Science and Technology of China

yanji111111@126.com+86 13705511311

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026